

Fabio Angeli

List of Publications by Citations

Source: <https://exaly.com/author-pdf/11203906/fabio-angeli-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

112
papers

4,822
citations

32
h-index

68
g-index

148
ext. papers

5,807
ext. citations

4.8
avg, IF

6.1
L-index

#	Paper	IF	Citations
112	The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. <i>European Journal of Internal Medicine</i> , 2020 , 76, 14-20	3.9	652
111	Adverse prognostic significance of new diabetes in treated hypertensive subjects. <i>Hypertension</i> , 2004 , 43, 963-9	8.5	398
110	Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. <i>Lancet, The</i> , 2009 , 374, 525-33	4.0	302
109	Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. <i>Hypertension</i> , 2005 , 46, 386-92	8.5	288
108	Atrial fibrillation in hypertension: predictors and outcome. <i>Hypertension</i> , 2003 , 41, 218-23	8.5	238
107	Short- and long-term incidence of stroke in white-coat hypertension. <i>Hypertension</i> , 2005 , 45, 203-8	8.5	230
106	Day-night dip and early-morning surge in blood pressure in hypertension: prognostic implications. <i>Hypertension</i> , 2012 , 60, 34-42	8.5	208
105	Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. <i>American Journal of Hypertension</i> , 2003 , 16, 895-9	2.3	208
104	Impact of blood pressure variability on cardiac and cerebrovascular complications in hypertension. <i>American Journal of Hypertension</i> , 2007 , 20, 154-61	2.3	128
103	Risk of cardiovascular disease in relation to achieved office and ambulatory blood pressure control in treated hypertensive subjects. <i>Journal of the American College of Cardiology</i> , 2002 , 39, 878-85	15.1	115
102	Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. <i>Journal of Hypertension</i> , 2008 , 26, 1282-9	1.9	99
101	Ambulatory blood pressure and cardiovascular outcome in relation to perceived sleep deprivation. <i>Hypertension</i> , 2007 , 49, 777-83	8.5	96
100	Association between periodontal disease and left ventricle mass in essential hypertension. <i>Hypertension</i> , 2003 , 41, 488-92	8.5	90
99	Masked hypertension: evaluation, prognosis, and treatment. <i>American Journal of Hypertension</i> , 2010 , 23, 941-8	2.3	78
98	Hypertension and Atrial Fibrillation: Doubts and Certainties From Basic and Clinical Studies. <i>Circulation Research</i> , 2018 , 122, 352-368	15.7	76
97	Electrocardiographic features of patients with COVID-19 pneumonia. <i>European Journal of Internal Medicine</i> , 2020 , 78, 101-106	3.9	70
96	More Versus Less Intensive Blood Pressure-Lowering Strategy: Cumulative Evidence and Trial Sequential Analysis. <i>Hypertension</i> , 2016 , 68, 642-53	8.5	63

95	The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction. <i>Vascular Health and Risk Management</i> , 2008 , 4, 971-81	4.4	62
94	Echocardiographic left ventricular hypertrophy in hypertension: marker for future events or mediator of events?. <i>Current Opinion in Cardiology</i> , 2007 , 22, 329-34	2.1	55
93	Systolic and diastolic blood pressure changes in relation with myocardial infarction and stroke in patients with coronary artery disease. <i>Hypertension</i> , 2015 , 65, 108-14	8.5	52
92	Home Blood Pressure Measurements Will Not Replace 24-Hour Ambulatory Blood Pressure Monitoring. <i>Hypertension</i> , 2009 , 54, 188-95	8.5	51
91	Improved cardiovascular risk stratification by a simple ECG index in hypertension. <i>American Journal of Hypertension</i> , 2003 , 16, 646-52	2.3	50
90	Regression of left ventricular hypertrophy and prevention of stroke in hypertensive subjects. <i>American Journal of Hypertension</i> , 2006 , 19, 493-9	2.3	48
89	Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis. <i>European Heart Journal</i> , 2009 , 30, 679-88	9.5	47
88	Ambulatory blood pressure for cardiovascular risk stratification. <i>Circulation</i> , 2007 , 115, 2091-3	16.7	46
87	Calcium channel blockade to prevent stroke in hypertension: a meta-analysis of 13 studies with 103,793 subjects. <i>American Journal of Hypertension</i> , 2004 , 17, 817-22	2.3	45
86	White-coat hypertension in adults. <i>Blood Pressure Monitoring</i> , 2005 , 10, 301-5	1.3	44
85	The clinical significance of white-coat and masked hypertension. <i>Blood Pressure Monitoring</i> , 2007 , 12, 387-9	1.3	43
84	COVID-19: ACE2centric Infective Disease?. <i>Hypertension</i> , 2020 , 76, 294-299	8.5	39
83	The evolution and refinement of traditional risk factors for cardiovascular disease. <i>Cardiology in Review</i> , 2012 , 20, 118-29	3.2	39
82	SARS-CoV-2 vaccines: Lights and shadows. <i>European Journal of Internal Medicine</i> , 2021 , 88, 1-8	3.9	34
81	Clinical usefulness of ambulatory blood pressure monitoring. <i>Journal of the American Society of Nephrology: JASN</i> , 2004 , 15 Suppl 1, S30-3	12.7	33
80	Diuretic treatment of hypertension. <i>Diabetes Care</i> , 2011 , 34 Suppl 2, S313-9	14.6	32
79	Prognostic value of serial electrocardiographic voltage and repolarization changes in essential hypertension: the HEART Survey study. <i>American Journal of Hypertension</i> , 2007 , 20, 997-1004	2.3	29
78	Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2012 , 6, 81-91	3.4	28

77	Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials. <i>Vascular Health and Risk Management</i> , 2009 , 5, 411-27	4.4	28
76	New-onset diabetes in treated hypertensive patients. <i>Current Hypertension Reports</i> , 2005 , 7, 174-9	4.7	27
75	Usefulness of QRS voltage correction by body mass index to improve electrocardiographic detection of left ventricular hypertrophy in patients with systemic hypertension. <i>American Journal of Cardiology</i> , 2014 , 114, 427-32	3	26
74	Tight versus standard blood pressure control in patients with hypertension with and without cardiovascular disease. <i>Hypertension</i> , 2014 , 63, 475-82	8.5	25
73	Left ventricular hypertrophy and obesity: only a matter of fat?. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2015 , 22, 29-41	2.9	24
72	Estimate of white-coat effect and arterial stiffness. <i>Journal of Hypertension</i> , 2007 , 25, 827-31	1.9	24
71	The 2020 International Society of Hypertension global hypertension practice guidelines - key messages and clinical considerations. <i>European Journal of Internal Medicine</i> , 2020 , 82, 1-6	3.9	20
70	Aliskiren versus ramipril in hypertension. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2010 , 4, 193-200	4	19
69	Is the definition of daytime and nighttime blood pressure prognostically relevant?. <i>Blood Pressure Monitoring</i> , 2008 , 13, 153-5	1.3	18
68	How can we use the results of ambulatory blood pressure monitoring in clinical practice?. <i>Hypertension</i> , 2005 , 46, 25-6	8.5	18
67	Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and coronavirus. <i>Journal of Hypertension</i> , 2020 , 38, 1190-1191	1.9	17
66	The prognostic legacy of left ventricular hypertrophy: cumulative evidence after the MAVI study. <i>Journal of Hypertension</i> , 2015 , 33, 2322-30	1.9	17
65	New-onset diabetes, antihypertensive treatment, and outcome. <i>Hypertension</i> , 2007 , 50, 459-60	8.5	17
64	Pharmacokinetic evaluation and clinical utility of azilsartan medoxomil for the treatment of hypertension. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013 , 9, 379-85	5.5	16
63	Clinical utility of ambulatory blood pressure monitoring in the management of hypertension. <i>Expert Review of Cardiovascular Therapy</i> , 2014 , 12, 623-34	2.5	14
62	Treatment strategies for osteoarthritis patients with pain and hypertension. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2010 , 2, 229-40	3.8	14
61	Fixed-dose combination therapy in hypertension: cons. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2012 , 19, 51-4	2.9	13
60	Amlodipine and celecoxib for treatment of hypertension and osteoarthritis pain. <i>Expert Review of Clinical Pharmacology</i> , 2018 , 11, 1073-1084	3.8	13

59	European and US guidelines for arterial hypertension: similarities and differences. <i>European Journal of Internal Medicine</i> , 2019 , 63, 3-8	3.9	12
58	The 2014 hypertension guidelines: implications for patients and practitioners in Asia. <i>Heart Asia</i> , 2015 , 7, 21-5	1.9	12
57	Safety and efficacy of aliskiren in the treatment of hypertension: a systematic overview. <i>Expert Opinion on Drug Safety</i> , 2012 , 11, 659-70	4.1	12
56	Hypertension and the J-curve phenomenon: implications for tight blood pressure control. <i>Hypertension Research</i> , 2013 , 36, 109-11	4.7	12
55	Prognostic value of circadian blood pressure changes in relation to differing measures of day and night. <i>Journal of the American Society of Hypertension</i> , 2008 , 2, 88-96		11
54	Impact of Chamber Dilatation on the Prognostic Value of Left Ventricular Geometry in Hypertension. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	10
53	Neutrophil count for the identification of postmenopausal hypertensive women at increased cardiovascular risk. <i>Obstetrics and Gynecology</i> , 2010 , 115, 695-703	4.9	9
52	The optimal blood pressure target for patients with coronary artery disease. <i>Current Cardiology Reports</i> , 2010 , 12, 302-6	4.2	9
51	Blood pressure increase after Pfizer/BioNTech SARS-CoV-2 vaccine. <i>European Journal of Internal Medicine</i> , 2021 , 90, 111-113	3.9	9
50	Very early initiation of statin therapy and mortality in patients with acute coronary syndrome. <i>Acute Cardiac Care</i> , 2012 , 14, 34-9		8
49	Pharmacokinetic, pharmacodynamic and clinical evaluation of aliskiren for hypertension treatment. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011 , 7, 115-28	5.5	8
48	Does brachial pulse pressure predict coronary events?. <i>Advances in Cardiology</i> , 2007 , 44, 150-159		8
47	Reversal of left ventricular hypertrophy: what have recent trials taught us?. <i>American Journal of Cardiovascular Drugs</i> , 2004 , 4, 369-78	4	8
46	Ambulatory blood pressure monitoring and prognosis in the management of essential hypertension. <i>Expert Review of Cardiovascular Therapy</i> , 2003 , 1, 79-89	2.5	8
45	Is the development of diabetes with antihypertensive therapy a problem?--Pro. <i>Journal of Clinical Hypertension</i> , 2006 , 8, 120-6	2.3	7
44	The natural history of white-coat hypertension in the long term. <i>Blood Pressure Monitoring</i> , 2005 , 10, 65-6	1.3	7
43	The pivotal link between ACE2 deficiency and SARS-CoV-2 infection: One year later. <i>European Journal of Internal Medicine</i> , 2021 , 93, 28-34	3.9	7
42	Angiotensin receptor blockers in hypertension. New insights from Japan. <i>Hypertension Research</i> , 2010 , 33, 394-7	4.7	6

41	Optimal Use of the Non-Inferiority Trial Design. <i>Pharmaceutical Medicine</i> , 2020 , 34, 159-165	2.3	5
40	Hypertensive urgencies and emergencies: Misconceptions and pitfalls. <i>European Journal of Internal Medicine</i> , 2020 , 71, 15-17	3.9	5
39	Joint effect of heart failure and coronary artery disease on the risk of death during hospitalization for COVID-19. <i>European Journal of Internal Medicine</i> , 2021 , 89, 81-86	3.9	5
38	How Low Should We Go With Blood Pressure?. <i>Circulation Research</i> , 2017 , 120, 27-29	15.7	4
37	Severity of COVID-19: The importance of being hypertensive. <i>Monaldi Archives for Chest Disease</i> , 2020 , 90,	2.7	4
36	Left Ventricular Hypertrophy and Coronary Artery Calcifications: A Dangerous Duet?. <i>American Journal of Hypertension</i> , 2018 , 31, 287-289	2.3	4
35	Role and prognostic value of individual ambulatory blood pressure components in chronic kidney disease. <i>Journal of Human Hypertension</i> , 2018 , 32, 625-632	2.6	4
34	Device-Pocket Hematoma After Cardiac Implantable Electronic Devices. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020 , 13, e008372	6.4	4
33	Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension. <i>Cardiology and Therapy</i> , 2021 , 10, 397-406	2.8	4
32	PK/PD evaluation of fimasartan for the treatment of hypertension Current evidences and future perspectives. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018 , 14, 533-541	5.5	3
31	Effects of barnidipine on blood pressure and left ventricular diastolic function in patients with hypertension and metabolic syndrome: A 12-week, open-label noncomparison study. <i>Current Therapeutic Research</i> , 2008 , 69, 207-20	2.4	3
30	Optimizing the definition of dippers and nondippers: is a 70-86% full glass empty?. <i>Journal of Hypertension</i> , 2008 , 26, 630-2	1.9	3
29	Renin Angiotensin System Blockers and Risk of Mortality in Hypertensive Patients Hospitalized for COVID-19: An Italian Registry.. <i>Journal of Cardiovascular Development and Disease</i> , 2022 , 9,	4.2	3
28	Electrocardiographic features of patients with COVID-19: One year of unexpected manifestations. <i>European Journal of Internal Medicine</i> , 2021 ,	3.9	3
27	Electrocardiography for diagnosis of left ventricular hypertrophy in hypertensive patients with atrial fibrillation. <i>International Journal of Cardiology: Hypertension</i> , 2019 , 1, 100004	1.6	2
26	Management of hypertension in the very old: an intensive reduction of blood pressure should be achieved in most patients. <i>Journal of Human Hypertension</i> , 2020 , 34, 551-556	2.6	2
25	Treatment strategies for isolated systolic hypertension in elderly patients. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 1713-1723	4	2
24	Response to Morning Surge, Dipping, and Sleep-Time Blood Pressure as Prognostic Markers of Cardiovascular Risk. <i>Hypertension</i> , 2013 , 61,	8.5	2

23	The emerging role of high-density lipoprotein cholesterol in hypertension trials. <i>Journal of Hypertension</i> , 2009 , 27, 458-60	1.9	2
22	Fixed-Dose Combination Therapy in Hypertension 2012 , 19, 51		2
21	Pharmacotherapy for hypertensive urgency and emergency in COVID-19 patients. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 1-8	4	2
20	Non-inferiority Trial Design in Drug Development: A Primer for Cardiovascular Healthcare Professionals. <i>American Journal of Cardiovascular Drugs</i> , 2020 , 20, 229-238	4	2
19	Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation and coexistent atrial fibrillation. <i>European Heart Journal</i> , 2021 , 42, 2019	9.5	2
18	High heart rate amplifies the risk of cardiovascular mortality associated with elevated uric acid. <i>European Journal of Preventive Cardiology</i> , 2021 ,	3.9	2
17	Benefits of more intensive versus less intensive blood pressure control. Updated trial sequential analysis.. <i>European Journal of Internal Medicine</i> , 2022 ,	3.9	2
16	Clinical Significance of the Blood Pressure Changes from Day to Night. <i>Current Hypertension Reviews</i> , 2011 , 7, 13-19	2.3	1
15	Emerging therapies in the management of hypertensive patients with osteoarthritis. <i>Clinical Investigation</i> , 2011 , 1, 125-136		1
14	Finding a place for aliskiren in the wide spectrum of blood pressure lowering agents. <i>Hypertension Research</i> , 2012 , 35, 17-9	4.7	1
13	An update on antithrombotic therapy in atrial fibrillation patients in long-term ambulatory setting after percutaneous coronary intervention: where do we go from here?. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 2033-2051	4	1
12	Blood Pressure Increase following COVID-19 Vaccination: A Systematic Overview and Meta-Analysis. <i>Journal of Cardiovascular Development and Disease</i> , 2022 , 9, 150	4.2	1
11	Alcohol intake and atrial fibrillation: A new topic in gender medicine. <i>European Journal of Internal Medicine</i> , 2020 , 76, 23-25	3.9	0
10	The Clinical Significance of New-Onset Diabetes Mellitus in Hypertension. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2008 , 15, 1-3	2.9	0
9	Prognostic Value of Ambulatory Blood Pressure Monitoring 2016 , 165-191		
8	Aggressive blood pressure reduction in patients at high vascular risk: is it dangerous?. <i>Italian Journal of Medicine</i> , 2012 , 6, 302-306	0.5	
7	Angiotensin-converting enzyme inhibitors 2012 , 14-29		
6	Antihypertensive drugs and coronary artery disease : evidence from controlled trials. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2005 , 12, 119-24	2.9	

5 Prognostic Value of Ambulatory Blood Pressure Monitoring **2007**, 225-252

4 Hypertensive Heart Disease. *Updates in Hypertension and Cardiovascular Protection*, **2018**, 189-212 0.1

3 Soluble CD40 ligand and outcome in patients with coronary artery disease undergoing percutaneous coronary intervention. *Clinical Chemistry and Laboratory Medicine*, **2022**, 60, 118-126 5.9

2 Role of Ambulatory Blood Pressure Monitoring in Prehypertension. *Updates in Hypertension and Cardiovascular Protection*, **2019**, 471-491 0.1

1 Chronic Kidney Disease and Left Ventricular Hypertrophy. Potent Modifiers of the Prognostic Impact of Circadian Blood Pressure Changes.. *Hypertension*, **2022**, HYPERTENSIONAHA12218969 8.5